Ipilimumab
An inhibitor of CTL A-4 lymphocyte domain used to treat melanoma (PMID 23714523). Reviews on management of AE at PMID 23772560, 24278787. Incidence of ILD higher if ipilumab and nivolumab are given concomitantly (PMID 25891304)
The Drug-Induced Cardiotoxicity Website and App
Frequency - Incidence
Incidence of cardiac adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for cardiac adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic